BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32781218)

  • 1. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
    Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.
    Milite C; Feoli A; Horton JR; Rescigno D; Cipriano A; Pisapia V; Viviano M; Pepe G; Amendola G; Novellino E; Cosconati S; Cheng X; Castellano S; Sbardella G
    J Med Chem; 2019 Mar; 62(5):2666-2689. PubMed ID: 30753076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
    Lenstra DC; Al Temimi AHK; Mecinović J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.
    Xiong Y; Li F; Babault N; Wu H; Dong A; Zeng H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
    Bioorg Med Chem; 2017 Aug; 25(16):4414-4423. PubMed ID: 28662962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of novel histone lysine methyltransferase G9a inhibitors (part 1): molecular design based on a series of substituted 2,4-diamino-7- aminoalkoxyquinazoline by molecular-docking-guided 3D quantitative structure-activity relationship studies.
    Feng T; Wang H; Zhang X; Sun H; You Q
    Med Chem; 2014 Jun; 10(4):426-40. PubMed ID: 24151879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
    Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
    J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
    Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wasney GA; Dong A; Barsyte D; Kozieradzki I; Senisterra G; Chau I; Siarheyeva A; Kireev DB; Jadhav A; Herold JM; Frye SV; Arrowsmith CH; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2009 Dec; 52(24):7950-3. PubMed ID: 19891491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
    Pappano WN; Guo J; He Y; Ferguson D; Jagadeeswaran S; Osterling DJ; Gao W; Spence JK; Pliushchev M; Sweis RF; Buchanan FG; Michaelides MR; Shoemaker AR; Tse C; Chiang GG
    PLoS One; 2015; 10(7):e0131716. PubMed ID: 26147105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wigle TJ; Wasney GA; Dong A; Senisterra G; Chau I; Siarheyeva A; Norris JL; Kireev DB; Jadhav A; Herold JM; Janzen WP; Arrowsmith CH; Frye SV; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2010 Aug; 53(15):5844-57. PubMed ID: 20614940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
    Leenders R; Zijlmans R; van Bree B; van de Sande M; Trivarelli F; Damen E; Wegert A; Müller D; Ehlert JE; Feger D; Heidemann-Dinger C; Kubbutat M; Schächtele C; Lenstra DC; Mecinović J; Müller G
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2516-2524. PubMed ID: 31350126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
    Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
    J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone Methyltransferases G9a/
    Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights for the design of protein lysine methyltransferase G9a inhibitors.
    Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
    Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach.
    López-López E; Rabal O; Oyarzabal J; Medina-Franco JL
    J Comput Aided Mol Des; 2020 Jun; 34(6):659-669. PubMed ID: 32060676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
    Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
    Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
    Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
    Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells.
    Zhang J; Yao D; Jiang Y; Huang J; Yang S; Wang J
    Bioorg Chem; 2017 Jun; 72():168-181. PubMed ID: 28460359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the G9a/GLP histone methyltransferase complex modulates anxiety-related behavior in mice.
    Wang DY; Kosowan J; Samsom J; Leung L; Zhang KL; Li YX; Xiong Y; Jin J; Petronis A; Oh G; Wong AHC
    Acta Pharmacol Sin; 2018 May; 39(5):866-874. PubMed ID: 29417943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.
    Xiong Y; Li F; Babault N; Dong A; Zeng H; Wu H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
    J Med Chem; 2017 Mar; 60(5):1876-1891. PubMed ID: 28135087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.